Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)

6 Months Ended

Jun. 30, 2023

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended June 30, 2023		Diagnostics				Therapeutics				Corporate				Total
Research and development expenses		$	1,057,046			$	49,219			$	—			$	1,106,265
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				882				1,293,416				1,294,298
Depreciation and amortization ⁽²⁾			9,527				—				17,608				27,135
Loss from operations ⁽³⁾			(1,066,573	)			(50,101	)			(1,311,024	)			(2,427,698	)
Other income, net ⁽⁴⁾			—				—				1,034,514				1,034,514
Loss from continuing operations			(1,066,573	)			(50,101	)			(276,510	)			(1,393,184	)
Total assets, net of depreciation and amortization:
United States		$	—			$	—			$	7,638,388			$	7,638,388
International			568,856				—				12,568				581,424

Three Months Ended June 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
International		$	6,519			$	—			$	—			$	6,519
Grant and other revenue			51,007				—				—				51,007
Total revenue			57,526				—				—				57,526
Cost of revenue, excluding depreciation and amortization			473				—				—				473
Research and development expenses			1,636,691				87,297				—				1,723,988
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,001				1,230,894				1,233,895
Depreciation and amortization ⁽²⁾			6,041				—				15,730				21,771
Loss from operations ⁽³⁾			(1,585,679	)			(90,298	)			(1,246,624	)			(2,922,601	)
Other expense, net ⁽⁴⁾			—				—				(76,858	)			(76,858	)
Net loss			(1,585,679	)			(90,298	)			(1,323,482	)			(2,999,459	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	2,043,815			$	2,093,815
International			384,294				—				25,596				409,890
Capital expenditures			40,221				—				8,436				48,657

Six Months Ended June 30, 2023		Diagnostics				Therapeutics				Corporate				Total
Research and development expenses		$	2,227,599			$	146,119			$	—			$	2,373,718
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,060				2,418,599				2,421,659
Depreciation and amortization ⁽²⁾			18,802				—				35,888				54,690
Loss from operations ⁽³⁾			(2,246,401	)			(149,179	)			(2,454,487	)			(4,850,067	)
Other income, net ⁽⁴⁾			—				—				1,980,553				1,980,553
Loss from continuing operations			(2,246,401	)			(149,179	)			(473,934	)			(2,869,514	)
Total assets, net of depreciation and amortization:
United States		$	—			$	—			$	7,638,388			$	7,638,388
International			568,856				—				12,568				581,424
Capital expenditures			15,068				—				—				15,068

Six Months Ended June 30, 2022		Diagnostics				Therapeutics				Corporate				Total
Sales revenue:
International		$	6,519			$	—			$	—			$	6,519
Grant and other revenue			51,007				—				—				51,007
Total revenue			57,526				—				—				57,526
Cost of revenue, excluding depreciation and amortization			473				—				—				473
Research and development expenses			2,626,578				266,664				—				2,893,242
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,001				3,018,045				3,021,046
Depreciation and amortization ⁽²⁾			12,081				—				32,568				44,649
Loss from operations ⁽³⁾			(2,581,606	)			(269,665	)			(3,050,613	)			(5,901,884	)
Other expense, net ⁽⁴⁾			—				—				(84,819	)			(84,819	)
Net loss			(2,581,606	)			(269,665	)			(3,135,432	)			(5,986,703	)
Total assets, net of depreciation and amortization:
United States		$	50,000			$	—			$	2,043,815			$	2,093,815
International			384,294				—				25,596				409,890
Capital expenditures			40,221				—				8,436				48,657